Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After Breast Cancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial

Khan, James S.; Hodgson, Nicole; Choi, Stephen; Reid, Susan; Paul, James; Hong, Nicole J. Look; Holloway, Catherine; Busse, Jason W.; Gilron, Ian; Buckley, D. Norman; McGillion, Michael; Clarke, Hance; Katz, Joel; Mackey, Sean; Avram, Ronen; Pohl, K; Rao‐Melacini, Purnima; Devereaux, P.J.

doi:10.1016/j.jpain.2019.02.010

Cited by 35 publications

(52 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lidocaine is a local anesthetic drug derived from cocaine, and widely used in clinical application such as anti-bacteria, anti-inflammation, local skin anesthesia and so on ( Caracas et al, 2009 ; Adler et al, 2017 ; Cizmarikova et al, 2020 ). An increasing number of evidences have demonstrated that lidocaine could affect the development of multiple tumors including ovarian and breast cancer ( Gao et al, 2018 ; Khan et al, 2019 ; Liu et al, 2021 ). For example, it was reported that intravenous infusion of lidocaine during operation was associated with improved overall survival of patients with pancreatic cancer ( Zhang et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Lidocaine Promoted Ferroptosis by Targeting miR-382-5p /SLC7A11 Axis in Ovarian and Breast Cancer

Sun

Zhang

2021

Front. Pharmacol.

View full text Add to dashboard Cite

Ovarian and breast cancer are prevalent female malignancies with increasing occurrence incidence and metastasis, significantly affecting the health and life quality of women globally. Anesthetic lidocaine has presented anti-tumor activities in the experimental conditions. However, the effect of lidocaine on ovarian and breast cancer remains elusive. We identified the important function of lidocaine in enhancing ferroptosis and repressing progression of ovarian and breast cancer. Our data showed that lidocaine further repressed erastin-inhibited ovarian and breast cancer cell viabilities. The treatment of lidocaine induced accumulation of Fe2+, iron and lipid reactive oxygen species (ROS) in ovarian and breast cancer cells. The ovarian and breast cancer cell proliferation was suppressed while cell apoptosis was induced by lidocaine in vitro. Lidocaine attenuated invasion and migration of ovarian and breast cancer cells as well. Regarding the mechanism, we found that lidocaine downregulated solute carrier family 7 member 11 (SLC7A11) expression by enhancing microRNA-382-5p (miR-382-5p) in the cells. The inhibition of miR-382-5p blocked lidocaine-induced ferroptosis of ovarian and breast cancer cells. MiR-382-5p/SLC7A11 axis was involved in lidocaine-mediated inhibition of ovarian and breast cancer cell proliferation in vitro. The miR-382-5p expression was down-regulated but SLC7A11 expression was up-regulated in clinical ovarian and breast cancer samples. Furthermore, the treatment of lidocaine repressed tumor growth of ovarian cancer cells in vivo, in which the miR-382-5p expression was increased while SLC7A11 expression was decreased. Consequently, we concluded that the lidocaine promoted ferroptosis by miR-382-5p/SLC7A11 axis in ovarian and breast cancer cells. The clinical value of lidocaine in the treatment of ovarian and breast cancer deserves to be proved in detail.

show abstract

Section: Introductionmentioning

confidence: 99%

Lidocaine Promoted Ferroptosis by Targeting miR-382-5p /SLC7A11 Axis in Ovarian and Breast Cancer

Sun

Zhang

2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…It is also used intravenously for its antiarrhythmic effect. Current studies reported that intravenous infusion of lidocaine showed analgesic effects and without serious adverse reaction in a variety of chronic pain,13,14 including PHN 15,16. Consecutive 3 mg/kg lidocaine infusion (once a week for 4 consecutive weeks) provided effective short-term pain relief in a cohort of neuropathic pain (PHN or CRPS) 17.…”

Section: Introductionmentioning

confidence: 99%

<p>Intravenous infusion of lidocaine enhances the efficacy of conventional treatment of postherpetic neuralgia</p>

Tan¹,

Ma²,

Yuan³

et al. 2019

JPR

View full text Add to dashboard Cite

BackgroundPostherpetic neuralgia (PHN) is one kind of severe neuropathic pain which currently cannot be effectively cured. Recent researches suggest that intravenous infusion of lidocaine has a therapeutic effect on neuropathic pain such as PHN; however, the optimal dose and frequency of lidocaine infusion and the effectiveness and safety of this treatment in PHN patients still needs more clinical research. The aim of this study was to evaluate the therapeutic effects of daily intravenous lidocaine infusion on the outcome of the routine treatment of PHN.MethodsSixty PHN patients were randomly divided into two groups: 1) control group (Control), treated with conventional therapies, such as antiepileptic pills, analgesics, neurotrophic medicines, paravertebral spinal nerve block and physiotherapy; 2) lidocaine group (Lido) received daily infusion of lidocaine (4 mg/kg) besides the conventional treatments. If the pain is not controlled sufficiently, additional tramadol is given and the average consumption of tramadol is calculated. Pain intensity was assessed before and after each infusion, and the number of breakthrough pain in the last 24 hrs were recorded. The incidence of adverse reactions related to intravenous lidocaine infusion was recorded.ResultsFor five consecutive days, numeric rating scale (NRS) scores were significantly decreased after 1 hr of intravenous infusion of lidocaine. Compared with Control, the NRS scores and the frequency of breakthrough pain in the Lido were significantly reduced. In addition, the extra tramadol consumption in the Lido was significantly lower than that in the Control, and the average hospital stay of patients in Lido was decreased. However, anxiety and depression scores showed no difference between Lido and Control.ConclusionDaily intravenous lidocaine (4 mg/kg for 5 days) enhanced the outcome of PHN treatment, reduced the amount of analgesic medicine and shortened the length of hospital stay with no obvious adverse side effects.

show abstract

“…In breast cancer surgery, an intraoperative lidocaine infusion appears to reduce the development of CPSP. 93,94 Postoperative lidocaine infusions should be considered in patients with refractory acute pain not responsive to opioid therapy, abdominal surgeries, and history of chronic pain. Typical lidocaine infusion dosages include a bolus of 1-1.5 mg/kg followed by a 1-3 mg/kg/h infusion; bolus dose can be omitted if the infusion is expected to continue for hours to days.…”

Section: Intravenous Lidocaine Infusionsmentioning

confidence: 99%

Postoperative Pain Management

Mazda

Jadin

Kahn

2021

Can Journ Gen Int Med

View full text Add to dashboard Cite

After surgery, over 80% of people experience moderate-to-severe acute pain. Poorly controlled postoperative pain limits recovery and is associated with detrimental short- and long-term morbidity. While surgeons have traditionally been responsible for postoperative pain management, all clinicians providing care for surgical patients have a basic understanding of common pharmacologic and interventional pain management strategies. In this review, we discuss the consequences of acute pain, approaches to pain assessment, and an overview of commonly used therapies to manage postoperative pain. RÉSUMÉAprès une opération, plus de 80 % des gens ressentent des douleurs aiguës modérées à intenses. Une douleur postopératoire mal maîtrisée limite le rétablissement et est associée à une morbidité défavorable à court et à long terme. Bien que les chirurgiens soient habituellement responsables du traitement de la douleur postopératoire, il est impératif que tous les cliniciens qui soignent des patients ayant subi une intervention chirurgicale aient une connaissance de base des stratégies pharmacologiques et interventionnelles courantes relatives au traitement de la douleur. Dans cette revue, nous abordons les conséquences de la douleur aiguë, les approches de l’évaluation de la douleur et un aperçu des traitements couramment utilisés pour traiter la douleur postopératoire.

show abstract

Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After Breast Cancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial

Cited by 35 publications

References 50 publications

Lidocaine Promoted Ferroptosis by Targeting miR-382-5p /SLC7A11 Axis in Ovarian and Breast Cancer

Lidocaine Promoted Ferroptosis by Targeting miR-382-5p /SLC7A11 Axis in Ovarian and Breast Cancer

<p>Intravenous infusion of lidocaine enhances the efficacy of conventional treatment of postherpetic neuralgia</p>

Postoperative Pain Management

Contact Info

Product

Resources

About